EffRx Attending the BIO International Convention in San Diego
The BIO International Convention, taking place June 3-6, 2024, is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with more than 18,500 industry leaders from across the globe. EffRx proactively seeks in-licensing opportunities for Europe in niche therapeutic areas, primarily interested in rare diseases, endocrinology, and musculoskeletal diseases, and will […]
EffRx Attending the 2024 WCO IOF-ESCEO Congress in London
EffRx Pharmaceuticals is attending 24th Edition of the WCO-IOF-ESCEO – World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases – which takes place in London on April 11-14, 2024. EffRx will have a booth featuring Binosto® (buffered soluble alendronate 70mg), the first and only buffered solution for the treatment of osteoporosis. The IOF Congress is one […]
EffRx is a Proud Supporter of Rare Disease Day, Taking Place on February 28
As every year, EffRx will be recognizing and supporting the annual Rare Disease Day. Rare Disease Day is the globally coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease. Since its creation in 2008, Rare Disease Day has played […]
EffRx Attending the Annual Meeting SSEDP / SGPED on 25. January 2024 in Berne
The Swiss Society for Pediatric Endocrinology and Diabetology (SGPED) comprises pediatric endocrinologists and individuals from allied health professions. EffRx, a sponsor of SGPED, is jointly committed to improving the care of children and adolescents with endocrinological diseases and diabetes mellitus. Every year, EffRx supported this annual meeting and was present with a booth showing the […]
